| Ytd | -10.30% | |
| 1y | 75.45% |
| Open | 7.37 | Prev Close | 6.79 | Low | 6.61 | High | 7.50 | Mkt Cap | 63.97M |
| Vol | 146.00 | Avg Vol | 43.78K | EPS | -23.01 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.05 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.68 | 200-d Avg | 7.62 | 1yr Est | 0.00 |
LONA News
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers th
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lo
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consens
LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the developmen
Citizens analyst Jason N. Butler upgrades LeonaBio (NASDAQ:LONA) from Market Perform to Market Ou
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ:LONA) with a Overweig
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(1.73) per share which beat the analyst consens
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(2.77) per share which missed the analyst conse
LeonaBio, Inc. 58,464,567 Shares of Common StockOffered by the Selling StockholdersThis prospectus r